[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07543861":3,"trial-entities:NCT07543861":101,"trial-summary:NCT07543861":104},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":34,"secondary_outcomes":51,"sex":52,"minimum_age":53,"maximum_age":14,"healthy_volunteers":54,"eligibility_criteria":55,"std_ages":70,"locations":73,"central_contacts":89,"overall_officials":96,"references":99,"see_also_links":100},"NCT07543861","HUM00280455","A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease","RECRUITING","2027-03","2026-08","2026-08-14","2026-05-15","University of Michigan","OTHER",null,"This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.","For phase 1, participants will attend up to 12 4-hour sessions using the dynamic standing desk. In addition to these sessions, there will be a clinical assessment at baseline and an outcome session (endpoint assessments). In total, there will be up to 14 sessions per participant. All sessions need to be completed within 6 weeks. At the baseline session, clinical measurements will be collected. These measures will be repeated in the outcome session.",[18],"Parkinson Disease",[],"INTERVENTIONAL","TREATMENT",[23],"PHASE1",{"count":25,"type":26},5,"ESTIMATED",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32},"DEVICE","Dynamic Standing Desk","Participants will stand at the desk for 4 hours per session. During each session, the desk will move to prompt the participant to take small steps. Participants will take breaks as needed. Each participant will complete up to 12 sessions in the span of 6 weeks.",[33],"Dynamic Standing Desk in People with Parkinsons",[35,39,42,45,48],{"measure":36,"description":37,"timeFrame":38},"Gait Speed","Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second.","Baseline and post-intervention (up to 6 weeks).",{"measure":40,"description":41,"timeFrame":38},"Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III","Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132.",{"measure":43,"description":44,"timeFrame":38},"Montreal Cognitive Assessment","Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30.",{"measure":46,"description":47,"timeFrame":38},"Timed Up and Go","Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment.",{"measure":49,"description":50,"timeFrame":38},"5 Times Sit to Stand","Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment.",[],"ALL","50 Years",false,{"inclusion":56,"exclusion":58,"raw_text":69},[57],"Diagnosis of Parkinson's Disease",[59,60,61,62,63,64,65,66,67,68],"Inability to stand or walk without an assistive device","History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects","Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.","History of symptomatic cardiovascular or pulmonary disease","History of active rheumatic arthritis","History of stroke or other neurologic conditions with significant residual sensorimotor deficits","History of disabling chronic pain syndrome requiring narcotic analgesics","Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \\\u003C24 and significant impairment in activities of daily living)","Venous ulcerative stasis or severe varicosities.","Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease\n\nExclusion Criteria:\n\n* Inability to stand or walk without an assistive device\n* History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects\n* Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.\n* History of symptomatic cardiovascular or pulmonary disease\n* History of active rheumatic arthritis\n* History of stroke or other neurologic conditions with significant residual sensorimotor deficits\n* History of disabling chronic pain syndrome requiring narcotic analgesics\n* Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \\\u003C24 and significant impairment in activities of daily living)\n* Venous ulcerative stasis or severe varicosities.\n* Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.",[71,72],"ADULT","OLDER_ADULT",[74],{"facility":75,"status":7,"city":76,"state":77,"zip":78,"country":79,"contacts":80,"geoPoint":86},"Domino's Farms","Ann Arbor","Michigan","48105","United States",[81],{"name":82,"role":83,"phone":84,"email":85},"Miriam Bohnen, DPT","CONTACT","734-936-1174","bohnenmi@med.umich.edu",{"lat":87,"lon":88},42.27756,-83.74088,[90,92],{"name":91,"role":83,"phone":84,"email":85},"Miriam Van Emde Boas, DPT",{"name":93,"role":83,"phone":94,"email":95},"Chatkaew Pongmala, PhD","734-936-0111","pchatkae@med.umich.edu",[97],{"name":93,"affiliation":12,"role":98},"PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":102,"biomarkers":103},[18],[],{"nct_id":4,"found":105,"summary":106,"prompt_version":116},true,{"design":107,"status":108,"heading":109,"summary":110,"follow_up":111,"word_count":112,"commitments":113,"compensation":114,"drugs_mentioned":115},"This is a small, early-stage (Phase 1) open-label study involving up to 5 participants.","completed","Pilot Study of Dynamic Standing in Parkinson's Disease","This study is looking at how a special standing desk, called a Dynamic Standing Desk, might help people with Parkinson's disease. The desk gently moves to encourage small steps while you stand. Researchers want to see if using this desk improves how well you walk and your overall movement. This is a small, early-stage study (Phase 1) involving up to 5 participants. You might be able to join if you have Parkinson's disease and can stand and walk without help. The study will measure your walking speed and movement before and after using the desk for up to 6 weeks. The study is currently unclear on its recruitment status.","Your progress will be measured at baseline and up to 6 weeks after the intervention.",109,"You would attend up to 12 four-hour sessions using the dynamic standing desk, plus a baseline and an outcome assessment, all within 6 weeks.","Not stated in the trial record.",[30],"v2"]